Drug intelligence / Profile preview

pianprinumab

Development stage: Preclinical
Lead developer: The Fifth Medical Center of the PLA General Hospital

Overview

Pianprinumab is an experimental drug currently being investigated in a single-arm, exploratory clinical study. It is being evaluated in combination with anlotinib hydrochloride for the first-line treatment of non-surgically resectable biliary system tumors. Further details regarding its mechanism of action, specific modality, or developer beyond the clinical trial runner are not publicly available.

Beyond the preview

Go deeper on pianprinumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pianprinumab.

Explore the full profile